# Antibiotic medicines: Supply chain

Source page: https://www.materialinsights.org/products/p_antibiotic_medicines/prod-supply/

#### Output and value

World output and its value, with year and source

| Measure | Value | Unit | Year | Source |
|---|---|---|---|---|
| Production capacity of Sandoz's Kundl site, finished dosage forms (one company's site; company statement) | 240 million | packages per year | 2024 | ^[15] |
| UNICEF's observed demand and procurement of amoxicillin dispersible tablets (one buyer, not world output) | 320 million | tablets | 2017 | ^[10] |
| 6-APA manufacturing sites in the world (five of them in China) | 7 | sites | 2026 | ^[2] |

as of 2026-11-14

#### Where it is made

Country shares of world output

| Country | Measure | Year | Source |
|---|---|---|---|
| China | An estimated 80-90% of world antibiotic ingredient production, and about 90% of world 6-APA capacity (a think-tank estimate with no stated method; a range, not a share) | 2026 | ^[2] |
| Austria | Sandoz's Kundl site; the company says it holds the only major remaining vertically integrated penicillin network in Europe; no country share given | 2024 | ^[15] |

as of 2026-11-14

#### Main companies

The largest makers and their shares

| Company | Country | Measure | Year | Source |
|---|---|---|---|---|
| Sandoz | Austria (Kundl production site) | Kundl finished dosage form capacity of 240 million packages a year; part of a EUR 200 million investment in the site; UNICEF lists Sandoz, Denmark, among four compliant suppliers of amoxicillin dispersible tablets | 2024 | ^[15]^[10] |
| Aurobindo Pharma | India | Approved in 2021 under the bulk drug PLI scheme, through Lyfius Pharma, for penicillin G (committed investment Rs 1,392 crore) and 7-ACA (Rs 813 crore); commissioned a penicillin G plant at Kakinada (15,000 tonnes a year) and a 6-APA plant through subsidiaries in April 2024, and restarted penicillin G production in July 2025 after a fire; the 7-ACA plant's status was not found | 2024 | ^[16]^[25]^[26] |
| Karnataka Antibiotics and Pharmaceuticals (KAPL) | India | Approved in 2021 under the bulk drug PLI scheme for 7-ACA, committed investment Rs 275 crore | 2021 | ^[16] |
| Medreich and Micro Labs (India), Remedica (Cyprus) | India and Cyprus | With Sandoz, the four suppliers UNICEF found compliant for amoxicillin dispersible tablets (May 2018 update) | 2018 | ^[10] |

as of 2026-11-14

#### Supply chains of the main makers

For the top three to five producing countries and India: share, where inputs and components come from, main makers and how variants differ

| Country | Inputs from | Makers | How variants differ | Year | Source |
|---|---|---|---|---|---|
| China | Not stated in the pages opened | Not named in the pages opened | An estimated 80-90% of world antibiotic ingredient production and about 90% of 6-APA capacity; five of the world's seven 6-APA sites | 2026 | ^[2] |
| India | China supplies 91.3% of all antibiotic ingredients imported into India (2026 report) | Aurobindo Pharma (penicillin G and 6-APA plants commissioned in 2024; 7-ACA approved under the PLI scheme), KAPL (7-ACA approved), Medreich and Micro Labs (finished tablets for UNICEF) | Not stated | 2026 | ^[2]^[16]^[25]^[10] |
| Austria | Not stated in the pages opened | Sandoz (Kundl) | Penicillin tablets; the company says it holds the only major remaining vertically integrated penicillin network in Europe | 2024 | ^[15] |

as of 2026-11-14

#### Industries that make it

The industries and kinds of firm that make it
 Made by

- [API manufacturers and CDMOs](https://www.materialinsights.org/industries/pharmaceuticals/) World A 2026 think-tank report says China makes an estimated 80-90% of antibiotic ingredients ^[2]; Aurobindo commissioned a penicillin G plant in India in 2024 ^[25].
- [Key starting material and intermediate makers](https://www.materialinsights.org/industries/pharmaceuticals/) World Intermediates such as 6-APA and 7-ACA: five of the world's seven 6-APA sites are in China ^[2]; Aurobindo commissioned a 6-APA plant in India in 2024 ^[25], and Aurobindo and KAPL were approved for 7-ACA ^[16].
- [Finished-dose formulators (branded and generic)](https://www.materialinsights.org/industries/pharmaceuticals/) World Sandoz's Kundl site makes finished penicillin medicines, 240 million packages a year ^[15].

as of 2026-11-14

#### Critical inputs

Inputs whose supply is concentrated, listed as critical or under export controls

| Input | Why | Concentration | Listing | Year | Source |
|---|---|---|---|---|---|
| antibiotic_intermediates (6-APA) | A core penicillin building block with few sites | About 90% of world 6-APA capacity is in China; only seven sites exist, five of them in China (2026 think-tank report; no method stated) | None found in the pages opened | 2026 | ^[2] |
| apis (antibiotic active ingredients) | The active ingredient of every antibiotic medicine | An estimated 80-90% of world production is in China; 91.3% of the antibiotic ingredients India imports come from China (2026 report) | None found in the pages opened | 2026 | ^[2] |

as of 2026-11-14

#### Rules and standards

Labels, efficiency and emission standards, producer responsibility, bans and tariffs

| Rule | Place | Year | What it does | Source |
|---|---|---|---|---|
| Schedule H1 of the Drugs and Cosmetics Rules, 1945 (G.S.R. 588(E) of 30 August 2013) | India | 2013 | A separate schedule for antibiotics, anti-TB drugs and certain habit-forming drugs; antibiotics in Schedules H and H1 may be sold by retail only on a registered medical practitioner's prescription (secondhand report of a CDSCO notice) | ^[17] |
| NPPA ceiling prices under the Drugs Prices Control Order 2013 | India | 2024 | Caps the price of listed medicines; the review order of 4 October 2024 put the ceiling for an azithromycin 500 mg tablet at Rs 11.67 | ^[19] |
| Revised Schedule M (good manufacturing practice) | India | 2025 | A February 2025 notification extended the timeline for implementation to 31 December 2025 for small and medium manufacturers with turnover below Rs 250 crore that apply with an upgrade plan | ^[20] |
| Effluent standards for the bulk drug and formulation (pharmaceutical) industry: draft G.S.R. 44(E) of 23 January 2020, final notification of 6 August 2021 | India | 2021 | The 2020 draft included antibiotic residue limits, largely derived from predicted no-effect concentrations for resistance selection; the final standards were notified on 6 August 2021, and a press report says the final notification dropped the antibiotic residue limits | ^[18]^[27]^[28] |
| Production-linked incentive (PLI) scheme for bulk drugs | India | 2021 | Approved Aurobindo Pharma for penicillin G and 7-ACA plants and KAPL for 7-ACA; Aurobindo commissioned its penicillin G plant in 2024 | ^[16]^[25] |
| WHO guidance on wastewater and solid waste management for antibiotic manufacturing | World | 2024 | The first WHO guidance on antibiotic pollution from manufacturing; gives regulators, procurers, inspectors and industry a basis for including pollution control in their standards; WHO says the issue is largely unregulated and quality assurance criteria typically do not address environmental emissions | ^[1] |
| UN political declaration target: Access antibiotics at least 70% of use by 2030 | World | 2024 | Countries committed at the 2024 UN General Assembly high-level meeting on AMR; only one in three reporting countries, territories and areas was meeting it on 2022 data | ^[8] |

as of 2026-11-14

#### India

India's output, trade, makers and rules in a short paragraph

India's private sector used 5,071 million defined daily doses of antibiotics in 2019, and the study puts 47.1% of that in formulations the central regulator had not approved ^[4]. Antibiotics are sold on prescription under Schedules H and H1 ^[17], and NPPA caps listed prices ^[19]. A 2026 report says China supplies 91.3% of India's antibiotic ingredient imports ^[2]; Aurobindo and KAPL were approved in 2021 for penicillin G and 7-ACA plants ^[16], and Aurobindo commissioned penicillin G and 6-APA plants in 2024 ^[25]. No source opened gives India's output in units.

as of 2026-11-14

#### Trade

World exports, the top exporters and importers and India, from UN Comtrade by HS code (worked out by the site)

| Flow | Value | Unit | Volume | Unit | Year | Source |
|---|---|---|---|---|---|---|
| World exports | 4.09 | USD billion | 127.5 | thousand tonnes | 2024 | UN Comtrade, HS 3004.10 |
| Average export value (calculated) | 32.11 | USD per kg | – | – | 2024 | UN Comtrade, HS 3004.10 |
| Exporter: India (18.2% of world exports) | 0.75 | USD billion | 26.6 | thousand tonnes | 2024 | UN Comtrade, HS 3004.10 |
| Exporter: Austria (15.5% of world exports) | 0.64 | USD billion | 16.4 | thousand tonnes | 2024 | UN Comtrade, HS 3004.10 |
| Exporter: China (8.5% of world exports) | 0.35 | USD billion | 26.3 | thousand tonnes | 2024 | UN Comtrade, HS 3004.10 |
| Exporter: France (7.9% of world exports) | 0.32 | USD billion | 4 | thousand tonnes | 2024 | UN Comtrade, HS 3004.10 |
| Exporter: Italy (7.9% of world exports) | 0.32 | USD billion | 6.9 | thousand tonnes | 2024 | UN Comtrade, HS 3004.10 |
| India exports (rank 1, 18.2% of world) | 0.75 | USD billion | 26.6 | thousand tonnes | 2024 | UN Comtrade, HS 3004.10 |
| India imports (rank 89, 0.1% of world) | 0 | USD billion | 0 | thousand tonnes | 2024 | UN Comtrade, HS 3004.10 |
| Importer: Saudi Arabia (15.8% of world imports) | 0.69 | USD billion | 9.3 | thousand tonnes | 2024 | UN Comtrade, HS 3004.10 |
| Importer: United States (10.4% of world imports) | 0.45 | USD billion | 8.3 | thousand tonnes | 2024 | UN Comtrade, HS 3004.10 |
| Importer: Egypt (9.6% of world imports) | 0.42 | USD billion | 7.7 | thousand tonnes | 2024 | UN Comtrade, HS 3004.10 |
| World exports | 15.17 | USD billion | 308.6 | thousand tonnes | 2024 | UN Comtrade, HS 3004.20 |
| Average export value (calculated) | 49.14 | USD per kg | – | – | 2024 | UN Comtrade, HS 3004.20 |
| Exporter: Italy (12.6% of world exports) | 1.92 | USD billion | 10.4 | thousand tonnes | 2024 | UN Comtrade, HS 3004.20 |
| Exporter: Canada (11.8% of world exports) | 1.79 | USD billion | 26.7 | thousand tonnes | 2024 | UN Comtrade, HS 3004.20 |
| Exporter: Switzerland (9.1% of world exports) | 1.38 | USD billion | 7.3 | thousand tonnes | 2024 | UN Comtrade, HS 3004.20 |
| Exporter: India (7.9% of world exports) | 1.2 | USD billion | 46.5 | thousand tonnes | 2024 | UN Comtrade, HS 3004.20 |
| Exporter: Germany (7.0% of world exports) | 1.06 | USD billion | 6 | thousand tonnes | 2024 | UN Comtrade, HS 3004.20 |
| India exports (rank 4, 7.9% of world) | 1.2 | USD billion | 46.5 | thousand tonnes | 2024 | UN Comtrade, HS 3004.20 |
| India imports (rank 46, 0.3% of world) | 0.05 | USD billion | 0.6 | thousand tonnes | 2024 | UN Comtrade, HS 3004.20 |
| Importer: United States (20.7% of world imports) | 3.16 | USD billion | 14.6 | thousand tonnes | 2024 | UN Comtrade, HS 3004.20 |
| Importer: China (10.8% of world imports) | 1.65 | USD billion | 8.5 | thousand tonnes | 2024 | UN Comtrade, HS 3004.20 |
| Importer: Switzerland (7.3% of world imports) | 1.11 | USD billion | 2.5 | thousand tonnes | 2024 | UN Comtrade, HS 3004.20 |

Worked out from data

#### Sources

1. [New global guidance aims to curb antibiotic pollution from manufacturing](https://www.who.int/news/item//03-09-2024-new-global-guidance-aims-to-curb-antibiotic-pollution-from-manufacturing) World Health Organization, 2024, news release of 3 September 2024
2. [Foreign control of antibiotic supply: American and European import reliance and systemic vulnerabilities (Report No. 2026/06)](https://www.geostrategy.org.uk/research/foreign-control-of-antibiotic-supply/) Council on Geostrategy with the Coalition for a Prosperous America, 2026, think-tank report by Andrew Rechenberg (economist, Coalition for a Prosperous America, an advocacy group) and Patrick Triglavcanin (Council on Geostrategy); ISBN 978-1-917893-22-0; no publication month, no method section and no footnotes for the figures
3. [Consumption of systemic antibiotics in India in 2019 (Koya, Ganesh, Selvaraj, Wirtz, Galea, Rockers)](https://doaj.org/article/d212568d4b16440993b12db2d59c9350) The Lancet Regional Health - Southeast Asia, vol. 4, p. 100025 (record on DOAJ), 2022, abstract only
4. [Antibiotics most responsible for drug resistance are overused - WHO report](https://www.who.int/news/item/29-04-2025-antibiotics-most-responsible-for-drug-resistance-are-overused---who-report) World Health Organization, 2025, news release of 29 April 2025; 2022 data
5. [Amoxicillin Dispersible Tablets: Market and Supply Update](https://www.unicef.org/supply/media/511/file/amoxicillin-dispersible-tablets-market-and-supply-update.pdf) UNICEF Supply Division, 2018, May 2018; Tables 1, 3 and 4
6. [Sandoz opens antibiotic production facility in Austria](https://chemanager-online.com/en/news/sandoz-opens-antibiotic-production-facility-in-austria) CHEManager International, 2024, 26 March 2024; company claims reported by a trade publication
7. [Aurobindo Pharma, KAPL get approval for promotion of manufacturing bulk drugs](https://medicaldialogues.in/news/industry/pharma/aurobindo-pharma-kapl-get-approval-for-promotion-of-manufacturing-bulk-drugs-73830) Medical Dialogues, 2021, 24 January 2021, by Ruchika Sharma, citing PTI and a Ministry of Chemicals and Fertilizers statement
8. [Rational Use Of Antibiotics For Limiting Antimicrobial Resistance: CDSCO lists down steps for Pharma cos, chemists and drug controllers](https://business.medicaldialogues.in/rational-use-of-antibiotics-for-limiting-antimicrobial-resistance-cdsco-lists-down-steps-for-pharma-cos-chemists-and-drug-controllers) Medical Dialogues, 2019, 26 December 2019, Medical Dialogues Bureau; secondhand report of a CDSCO notice
9. [The Indian government publish draft legislation to limit antibiotic pollution from manufacturing](https://www.gu.se/en/news/the-indian-government-publish-draft-legislation-to-limit-antibiotic-pollution-from-manufacturing) University of Gothenburg, 2020, 13 February 2020; the notification number and date appear only in the page's link
10. [NPPA Hikes Prices of Key Antibiotics Azithromycin, Amoxicillin Clavulanic Acid](https://medicaldialogues.in/news/industry/pharma/nppa-hikes-prices-of-key-antibiotics-azithromycin-amoxicillin-clavulanic-acid-143145) Medical Dialogues, 2025, 12 February 2025, by Farhat Nasim; reports the review order dated 4 October 2024
11. [Relief for Drugmakers: Health Ministry Extends Schedule M Deadline, Sets Compliance Terms](https://medicaldialogues.in/amp/news/industry/pharma/relief-for-drugmakers-health-ministry-extends-schedule-m-deadline-sets-compliance-terms-143208) Medical Dialogues, 2025, 13 February 2025; quotes the notification's proviso
12. [Aurobindo Pharma commissions 4 manufacturing plants for PenicillinG, other products](https://medicaldialogues.in/news/industry/pharma/aurobindo-pharma-commissions-4-manufacturing-plants-for-penicilling-other-products-126567) Medical Dialogues (Ruchika Sharma), 2024, 1 April 2024
13. [Aurobindo Pharma arm restarts production at Kakinada Penicillin-G plant after fire incident](https://medicaldialogues.in/news/industry/pharma/aurobindo-pharma-arm-restarts-production-at-kakinada-penicillin-g-plant-after-fire-incident-150927) Medical Dialogues (Ruchika Sharma), 2025, 1 July 2025
14. [Reply of MoEF in O.A. No. 497 of 2024 News item titled Impact of Pharmaceutical toxicity on the environment and its regulatory aspects](https://www.greentribunal.gov.in/sites/default/files/news_updates/Reply of MoEF in O.A. No. 497 of 2024 News item titled Impact of Pharmaceutical toxicity on the environment and its regulatory aspects.pdf) Ministry of Environment, Forest and Climate Change, Government of India (filed with the National Green Tribunal), 2024, reply dated 14 August 2024, paras 4, 5 and 7
15. [Green Ministry drops Antibiotic effluent limits from new rules](https://thehealthmaster.com/?p=27104) The Health Master (from ET Healthworld), 2021, 14 August 2021; secondhand press report

## Other sections

- [Summary](https://www.materialinsights.org/products/p_antibiotic_medicines/index.md)
- [Working](https://www.materialinsights.org/products/p_antibiotic_medicines/prod-working/index.md)
- [Bill of materials](https://www.materialinsights.org/products/p_antibiotic_medicines/prod-bom/index.md)
- [Use case](https://www.materialinsights.org/products/p_antibiotic_medicines/prod-use/index.md)
- [Footprint](https://www.materialinsights.org/products/p_antibiotic_medicines/prod-footprint/index.md)
- [Evolution](https://www.materialinsights.org/products/p_antibiotic_medicines/prod-evolution/index.md)
- [Interventions](https://www.materialinsights.org/products/p_antibiotic_medicines/prod-interventions/index.md)
